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Background: Prion diseases are neurodegenerative diseases that are characterized by the conversion of the cellular
prion protein (PrPc) into a pathogenic isoform (PrPSc). It is known that neurodegeneration is often accompanied by
the disturbance of cholesterol homeostasis. We have recently identified a set of genes that were upregulated after
prion infection of N2a neuronal cells (Bach et al., 2009).
Results: We have now used ultra-deep sequencing technology to profile all microRNAs (miRNA) that could be
associated with this effect in these N2a cells. Using stringent filters and normalization strategies we identified a
small set of miRNAs that were up- or downregulated upon prion infection. Using bioinformatic tools we predicted
whether the downregulated miRNAs could target mRNAs that have been previously identified to enhance
cholesterol synthesis in these cells. Application of this joint profiling approach revealed that nine miRNAs potentially
target cholesterol-related genes. Four of those miRNAs are localized in a miRNA-dense cluster on the mouse
X-chromosome. Among these, twofold downregulation of mmu-miR-351 and mmu-miR-542-5p was confirmed by
qRT-PCR. The same miRNAs were predicted as putative regulators of the sterol regulatory element-binding
factor 2 (Srebf2), the low-density lipoprotein receptor (Ldlr) or the IPP isomerase.
Conclusions: The results demonstrate that joined profiling by ultra-deep sequencing is highly valuable to identify
candidate miRNAs involved in prion-induced dysregulation of cholesterol homeostasis.
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Transmissible spongiform encephalopathies (TSE) or
prion diseases comprise a group of neurodegenerative
diseases that include bovine spongiform encephalopathy
(BSE) in cattle, scrapie in sheep, and Creutzfeldt-Jakob
disease (CJD) in humans [1]. Prion diseases are asso-
ciated with the conversion of the cellular prion protein
(PrPC) into a pathogenic isoform (PrPSc) [2,3]. Aggrega-
tion of PrPSc in neurons coincides with neuronal decay
that finally leads to neurodegeneration. The molecular
mechanism underlying prion-induced metabolic changes
within infected cells are still poorly understood [4-6].
Several lines of evidence indicate that imbalances in
the homeostasis of cholesterol are linked to the progres-
sion of neurodegenerative disorders including prion* Correspondence: dmotzkus@dpz.eu
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reproduction in any medium, provided the ordiseases [7-9]. Membrane-bound cholesterol is essential
for the localization of PrPC in lipid rafts and for the for-
mation of PrPSc [10]. Inhibition of cholesterol biosyn-
thesis reduces the formation of PrPSc and prolongs the
survival time of scrapie-infected mice [11-13]. Cell cul-
ture models have been widely used to identify molecules
that link cholesterol synthesis to PrPSc formation [14].
Prion infected neuroblastoma cells upregulate a number
of genes, among others HMG-CoA synthase (Hmgcs),
HMG-CoA reductase (Hmgcr), IPP isomerase (Idi1), and
the sterol regulatory element binding factor 2 (Srebf2),
that are involved in the cholesterol biosynthesis pathway.
In addition, expression of the low density lipoprotein
(Ldl)-receptor is enhanced and leads to an increased up-
take of cholesterol after prion infection [15].
Both, uptake and synthesis of cholesterol [16-20] as
well as maintenance of hepatic function [21] are essen-
tially influenced by the action of microRNAs (miRNAs).
MiRNAs are potent regulators of gene expression thatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Montag et al. BMC Genomics 2012, 13:486 Page 2 of 8
http://www.biomedcentral.com/1471-2164/13/486can act on the posttranscriptional level. These on average
22 nt long non-protein coding RNAs are derived from
primary transcripts (pri-miRNA) that are sequentially
processed into their mature form by the RNase III type
nucleases DROSHA and DICER [22]. The mature miR-
NAs are sequestered into RNA-induced silencing com-
plexes (RISCs) and recruit complementary mRNAs that,
as a result, are degraded or translationally repressed [23].
Evidence accumulates that miRNAs are also involved in
most neurodegenerative disorders that include Parkin-
sonism [24], Huntington’s Chorea [25], Alzheimer’s dis-
ease [26], and also prion disease [27,28].
Since miRNAs reduce the transcript levels of their tar-
get mRNAs on a genome-wide scale [29-33], the parallel
examination of a miRNome and a transcriptome com-
bined with a miRNA target analysis can be used to iden-
tify miRNA:mRNA interaction partners. This so-called
“genome-wide joint profiling” has been successfully ap-
plied to identify pathologically relevant miRNA:mRNA
interactions in Alzheimer’s disease [34] and neuronal
HIV-infection [35].
In the present study we applied joint profiling to
prion-infected neuronal cell cultures. Using ultra-deep
sequencing we obtained several millions of small RNA
sequence reads. Stringent filtering, co-expression and
target analysis identified nine miRNAs that showed mul-
tiple targets in cholesterol-dependent mRNAs. Four of
those miRNAs, namely mmu-miR-351, mmu-miR-503,
mmu-miR-503*, and mmu-miR-542-5p, are clustered in
a miRNA dense region on the mouse X-chromosome.
Our results show that joint profiling of miRNA and
mRNA is an effective approach to identify relevant
miRNA:mRNA candidate pairs that could be used for




The mouse neuroblastoma cell line N2a (CCL-131, Ameri-
can type Culture Collection, Rockville, MD) was cultured
and sibling clones were infected in parallel with brain
homogenate from scrapie-infected mice (strain 22 L) or
from healthy controls as previously described [15]. After
the 18th passage RNA was extracted with the RNeasy mini
kit (Qiagen). The integrity of the RNA samples was deter-
mined by capillary electrophoresis on a Bioanalyzer (Agi-
lent Technologies) according to the supplier’s instructions.
The RNA concentration was determined photometrically
at 260 nm on a NanoDrop (PeqLab) and 5 μg of each sam-
ple were applied to ultra-deep sequencing.
Ultra-deep sequencing of small RNAs
Construction of cDNA libraries, cluster generation and
subsequent ultra-deep sequencing on a Solexa/Illuminaplatform was performed at the Allan Wilson Centre
Genome Service (AWCGS), New Zealand. In brief, 5 μg
of total RNA from each sample was size-fractionated by
15% polyacrylamide electrophoresis (PAGE). The small
RNA fraction (18–35 nucleotides (nt)) was extracted and
ligated to 5’- and 3’-RNA adaptors using T4 RNA ligase.
The RNA-adaptor constructs were purified and reverse
transcribed. Clusters were generated by hybridization of
the samples to the flow cell, chemical conversion to
ssDNA, blocking of the 3’-OH and hybridization of se-
quencing primers. Ultra-deep sequencing was performed
using one flow cell channel per sample.Bioinformatic analyses
Compression of library data was achieved by annotating
the frequency of each unique sequence into its respective
identifier, thereby removing multiple reads in FASTA
format. Sequences with a frequency <10 were discarded.
Both preprocessing steps were implemented as Perl
scripts and led to a speed-up of all further computations
by a factor of about 18. Processed libraries were aligned
to miRBase release 14.0 with NCBI BLAST (blastall ver-
sion 2.2.18) using standard settings without DUST filter
(option -F F). Identification of miRNAs by BLAST
required perfect alignment over the total miRNA length
minus a tolerance offset of 3 nt. MiRNA target sites in
the 3’-UTR of murine mRNAs Srebf2, Hgmcr, Hgmcs1,
Mvk, Idi1, Fdft1, Cyp51, Sc4mol, and Ldlr were pre-
dicted using miRanda (version 3.0; [36]) with the follow-
ing parameter settings: minimum score 130, minimum
free energy −19 kcal/mol, conservation off, scaling par-
ameter 4, gap open penalty −8.0, gap extend penalty
−4.0. Ribosomal 28S, 18S, 5.8S and 5S rRNAs were
BLASTed against miRBase release 14.0.miRNA profiling by quantitative real-time PCR
Ten ng of total RNA from scrapie- and mock-infected
N2a cells were reverse transcribed (TaqMan MicroRNA
Reverse Transcription Kit, Applied Biosystems). The rela-
tive expression levels of mmu-miR-503, mmu-miR-503*,
mmu-miR-351 and mmu-miR-542-5p was determined in
a stem-loop based quantitative real-time PCR (qRT-PCR)
assay (TaqMan MicroRNA Assay, Applied Biosystems)
according to the supplier's instructions. Cycling was per-
formed after initial denaturation for 10 min at 95°C for
45 cycles with 95°C for 15 sec and 60°C for 45 sec in a
7500 Real Time PCR System (Applied Biosystems). Rela-
tive expression levels were calculated according to the
ΔΔCT-method [37] using the non-regulated miRNA
hsa-miR-106b* as a housekeeping RNA. Statistical sig-
nificance was determined by two way ANOVA with
Bonferroni post test (*** p < 0.001).
Figure 1 Flow chart. Successive filtering steps of ultra-deep
sequencing reads from prion-infected ScN2a (left) and
mock-infected N2a-mock (right) cells. Steps of the joint profiling
approach are denoted in the shaded box.
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In the present study we applied joint profiling to prion-
infected neuronal cell cultures. Therefore we performed
co-expression analysis of miRNAs and mRNAs com-
bined with a stringent miRNA target prediction to iden-
tify relevant miRNA:mRNA pairs. This combined
approach will be referred to as joint profiling. Reliable
joint profiling by a direct comparison of miRNA and
mRNA expression data depends on the use of identical
samples for both studies. Thus we have used the prion-
infected neuroblastoma N2a cell model that had been
generated for whole genome transcriptome profiling
[15]. In brief, the N2a cells were infected in parallel with
brain homogenate derived from terminally ill mice
infected with the scrapie strain 22 L (ScN2a) or from
mock-infected healthy mice (N2a-mock) as previously
reported [15]. We then extracted total RNA from ScN2a
and N2a-mock cells. To confirm high quality RNA we
conducted nano-scale electrophoresis that showed a high
RNA integrity number (RIN) of 9.4 and 9.6 in both sam-
ples, respectively.
The recent development of high-throughput sequen-
cing technologies (also referred to as ultra-deep sequen-
cing) allows for the comprehensive recording of all
nucleic acid sequences in virtually any biological sample.
We decided to use the Solexa platform that is especially
suitable for miRNA analysis due to its immense capacity
to generate high numbers of short sequence reads with
high accuracy. To achieve the highest possible sensitivity
both samples were enriched for small RNAs with a cut-off
range from 18 to 35 nt. To further increase the sequencing
depth (i.e. number of sequence reads per sample) we used
one capillary per sample with a capacity of approxi-
mately 175 million base pairs. Our ultra-deep sequen-
cing analysis resulted in the generation of 5.8 x 106 and
4.2 x 106 sequence reads from ScN2a and N2a-mock
cells, respectively.
For the generation of miRNA profiles from these li-
braries, successive filtering and normalization steps were
implemented (Figure 1). As a first step, compression of
data was achieved by merging of identical sequence
reads and encoding their frequency into the respective
sequence identifier. Since the population of small RNAs
must be expected to include mRNA degradation pro-
ducts with limited significance [38] we increased the
specificity of our dataset by exclusion of rare sequences.
We arbitrarily applied a cut-off for reads with a fre-
quency <10. It should be noted that this stringent cut-
off results in loss of information, but is required to re-
duce the expected false positive rate. Identification of all
expressed murine miRNAs in our samples was achieved
by annotation of the filtered dataset to the miRBase
14.0. Our BLAST analysis allowed up to three
mismatches at the 5’- or 3’-end of each miRNA,respectively. Although this leads to loss of specificity
regarding closely related miRNAs, it enabled the identi-
fication of miRNA-processing variants that differ from
the miRBase entries [39,40].
To date, several miRNAs have been removed from
miRBase due to the fact that the sequences were identi-
cal to ribosomal RNAs (rRNAs), e.g. miR-560 and hsa-
miR-923 from miRBase release 13.0 (ftp://mirbase.org/
pub/mirbase/13.0/miRNA.dead.gz). To ensure that our
dataset would not include such rRNA-derived sequences,
we did an additional BLAST analysis that compared the
entire murine miRBase dataset with mouse 28S, 18S, 5S
and 4.5S rRNA NCBI entries. We found that 16 miRNAs
appeared to be rRNA fragments and thus were removed
from our analysis. Most, but not all of these rRNA frag-
ments were also described by others [41] and have
meanwhile been deleted from mirBase. However, mmu-
miR-709 and mmu-miR-1195 are identical to ribosomal
sequences and still valid in the current mirBase release
19.
After this successive filtering we identified 256 miR-
NAs expressed in mock-infected and 241 expressed in
Table 1 Regulated miRNAs in ScN2a cells as compared to
mock infected controls




mmu-miR-351 88 0 downregulated
mmu-miR-139-5p 21 0 downregulated
mmu-miR-690 35 0 downregulated
mmu-miR-330* 36 0 downregulated
mmu-miR-378* 22 0 downregulated
mmu-miR-485* 27 0 downregulated
mmu-miR-375 65 11 −4.23
mmu-miR-503 64 12 −3.82
mmu-miR-203 47 10 −3.37
mmu-miR-542-5p 46 14 −2.35
mmu-miR-322* 33 11 −2.15
mmu-miR-503* 29 10 −2.08
mmu-miR-125b-3p 43 15 −2.05
mmu-miR-15b* 36 52 2.02
mmu-miR-598 83 120 2.02
mmu-miR-411 41 60 2.04
mmu-miR-743b-5p 47 69 2.05
mmu-miR-126-3p 70 106 2.12
mmu-miR-708 22 34 2.16
mmu-miR-883a-3p 10 16 2.23
mmu-miR-181d 184 295 2.24
mmu-miR-210 223 370 2.32
mmu-miR-497 13 22 2.36
mmu-miR-101a 12 21 2.44
mmu-miR-181c 33 61 2.58
mmu-miR-128 30 58 2.70
mmu-miR-338-5p 10 23 3.21
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to 261 individual miRNAs (Additional file 1).
For the identification of regulated miRNAs, the librar-
ies derived from scrapie-infected and mock-infected cells
needed to be normalized. The normalization of ultra
deep sequencing data has been reported to be a crucial
step in interpreting regulation [38]. Parameswaran and
colleagues have described two alternative methods, (1)
the normalization to total small RNAs sequenced for
each library or (2) the normalization against the total
number of miRNAs in the respective samples. Applying
both normalization methods to our filtered datasets we
obtained similar results (data not shown). However,
normalization against the total number of miRNAs bears
the risk of creating a bias in case that a high proportion
of miRNAs is regulated. Therefore we chose to
normalize against the total number of sequence reads.
Next we aimed to identify miRNAs that were differen-
tially expressed in scrapie-infected cells as compared to
mock-infected controls. Regulation of miRNAs was con-
sidered to be robust if the relative abundance differed at
least twofold between both libraries. Using this analysis
strategy we found 14 upregulated and seven downregu-
lated miRNAs in addition to a number of miRNAs that
were solely expressed in ScN2a or N2a-mock cells. Since
we had restricted our analysis to sequences that had
been read more than ten times, we filtered the solely
expressed miRNAs for those that were detected more
than 20 times to reach the criterion of twofold regula-
tion. Six miRNAs from N2a-mock cells matched this cri-
terion and were termed “downregulated” without
assigning a specific regulation factor. The resulting 14
upregulated and 13 downregulated miRNAs with their
corresponding sequence reads are listed in Table 1.
It is known that the upregulation of miRNAs results in
the downregulation of their specific target genes. Vice
versa, downregulation of miRNAs could lead to the
upregulation mRNA levels, presumably by a de-
repression mechanism [42]. Accordingly, some or all of
the 13 downregulated miRNAs may be responsible for
the upregulation of those mRNAs that induce prion-
associated disturbance of cholesterol homeostasis.
In the light of these considerations we conducted a
miRNA target search. We examined the 3’-UTRs of the
cholesterogenic mouse genes (Srebf2, Hgmcs, Hgmcr,
Mvk, Idi1, Fdft1, CYP51, Sc4mol, and Ldlr; [15]) for pu-
tative binding sites for the 13 downregulated miRNAs.
Four out of 13 miRNAs were not predicted to bind any
of the nine target genes. However, nine miRNAs showed
multiple targets in at least one of these mRNAs (Table 2).
Interestingly, four of those miRNAs, namely mmu-miR-
351, mmu-miR-503, mmu-miR-503*, and mmu-miR-
542-5p are located in a genomic cluster within 5 kb on
the mouse X-chromosome.We next validated the regulation of the miRNAs from
this cluster (mmu-miR-351, mmu-miR-503, mmu-miR-
503*, and mmu-miR-542-5p) by qRT-PCR. For
normalization we used the mmu-miR-106b* as a house-
keeping miRNA, presuming that it was expressed at con-
stant and robustly high levels. Using a commercial kit,
mmu-miR-503 was not detected by qRT-PCR analysis.
To provide comparability among the quantification of
the different miRNAs we did not modify the recom-
mended protocol of the commercial detection kit in
order to achieve detection of mmu-miR-503. In compari-
son, mmu-miR-503* could be detected, however, we
could not confirm regulation. The fact that in ultra-deep
sequencing the number of sequence reads and the upre-
gulation factors were both at the borderline may have
Table 2 Predicted target sites in the 3’-UTR of genes involved in the cholesterogenic pathway for downregulated
miRNAs
miRNA Coordinates (NCBIM37) Number of targets
Hgmcs1 Hgmcr Idi1 Fdft1 CYP51 Sc4mol Ldlr Srebf2
mmu-miR-139-5p 7: 108623890–108623957 [+] 1
mmu-miR-330* 7: 19766814–19766911 [+] 1 2 1 2
mmu-miR-125b-3p 9: 41390009–41390085 [+] 1 1 1 1
mmu-miR-690 16: 28600021–28600129 [−] 1
mmu-miR-378* 18: 61557489–61557554 [−] 2
mmu-miR-503 X: 50407161–50407231 [−] 1 2 2
mmu-miR-503* X: 50407161–50407231 [−] 1
mmu-miR-351 X: 50406432–50406530 [−] 1 1 1 1 5 3
mmu-miR-542-5p X: 50402580–50402664 [−] 1
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by qRT-PCR. However, the regulation of the more abun-
dantly expressed miRNAs mmu-miR-351 and −542-5p
was confirmed by qRT-PCR, indicating to a high validity
of the ultra-deep sequencing (Figure 2). Furthermore the
magnitude of downregulation in scrapie-infected versus
mock-infected cells of mmu-miR-351 and mmu-miR-
542-5p was comparable to that estimated by ultra-deep
sequencing. In summary, our joint profiling approach
lead to the identification of two miRNA candidates that
correlate with disturbance in cholesterol homeostasis in
prion-infected cells.Discussion
Ultra-deep sequencing represents a powerful technology
for the comprehensive assessment of the whole miR-
Nome in a given sample in a presumably unbiased man-
ner. Using Solexa technology we have generated five
million independent short sequence reads per sample.
Highly abundant miRNAs, such as mmu-let-7c, mmu-
miR-24, and mmu-miR-99b were sequenced on average
20,000 times. This corresponds to an enhanced sensitiv-
ity of three orders of magnitude in comparison to trad-
itional cloning and subsequent Sanger sequencing
strategies in early pioneer studies [43]. Since high sensi-
tivity mostly results in reduced specificity we used a
panel of stringent filters to identify miRNAs that were
robustly expressed. Contemporaneously we could ex-
clude fragments derived from ribosomal RNA that were
misleadingly annotated as miRNAs in miRBase 14.0. The
high specificity of our approach is reflected by the detec-
tion of more than 1,000 sequence reads of the neuronally
expressed paralogues miR-103/107 [44] and miR30a/d
[45], whereas liver-enriched miR-122 was not expressed
in N2a cells. This is in accordance with previous studies
that did not detect significant amounts of these miRNAs
in the brain [28,43,46].Ultra-deep sequencing data can be used for relative
quantification, but the resulting accuracy is strictly
dependent on the used scaling method [47]. We have
normalized our miRNAs expression profiles to the re-
spective library size as suggested [48]. To ensure the ap-
plicability of this normalization method to identify
regulated miRNAs we performed qRT-PCR. By compari-
son of these two independent methods we could confirm
downregulation of mmu-miRs −351 and −542-5p. Fur-
thermore, the observed differences in miRNA expression
were consistent, regardless whether they were deter-
mined by UDS or qRT-PCR, although significant regula-
tion of one miRNA could not be confirmed.
It was recently reported that murine mmu-miRNA-146a
is upregulated in scrapie [27], and BSE-infected [49] mice.
miR-146a can be activated upon LPS treatment via Toll-
like receptors TLR2 and TLR4. Upon overexpression,
mmu-miR-146a modulates transcription of genes
involved in cell movement and adhesion, mediators of
inflammation and a set of genes involved in RNA post-
transcriptional regulation [49]. Comparison of N2a vs
ScN2a cells revealed a 1.6 fold upregulation of mmu-
miR-146a that failed to match our criteria for further ana-
lysis. This is similar to the regulation upon BSE-infection
in macaques [28]. It may also reflect the specificity of cer-
tain microRNAs in rare human prion diseases that was
recently reported [50].
Our approach revealed 14 upregulated and 13 down-
regulated miRNAs in ScN2a cells as compared to
mock-infected controls. The downregulated miRNAs
were used as queries for target analysis to identify mu-
tual miRNA:mRNA interaction partners that might be
responsible for prion-associated induction of cholesterol
synthesis. Linking a miRNA to its downstream targets
is a major challenge in miRNA biology and only few
miRNA:mRNA pairs have been experimentally con-
firmed yet. A variety of bioinformatic algorithms have
been developed which predict potential binding sites
Figure 2 qRT-PCR analysis of clustered miRNAs in
scrapie-infected N2a cells. Ten ng of total RNA from ScN2a and
N2a-mock cells were applied to miRNA-specific cDNA synthesis.
Subsequent qRT-PCR was performed using equivalent amounts of
1.3 ng RNA. Relative miRNA expression was analyzed by ΔΔCT
method [37] using the non-regulated miRNA mmu-miR-106b* as a
housekeeping RNA and the non-infected cells as a calibrator.
Statistical significance was determined by student-t-test (non-
parametric with Welch’s correction, *** p < 0.001). The mean
regulation factor ± SD of duplicates from three independent
experiments are shown. Abbreviation n.d.; not detected.
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[51]. Some, but not all limitations of miRNA target pre-
dictions are caused by the inaccuracy of the underlying
algorithm. Identification of relevant miRNA:mRNA
pairs can also fail if one, the miRNA or the mRNA, is
not present in the relevant cell or tissue. Using our
miRNA expression profile and the known mRNA ex-
pression profile of the N2a cells we could strongly limit
the assumed production of false positive or false nega-
tive results. We used the miRanda algorithm [36] to
predict putative binding sites of the downregulated
miRNAs in the 3’-UTRs of prion-induced mRNAs
related to cholesterol homeostasis [15].
Four downregulated miRNAs could not be linked to
the upregulated cholesterogenic genes. These miRNAs
have neither been described to be involved in cholesterol
homeostasis nor in prion disease. However, nine out of
the 13 downregulated miRNAs were predicted to have at
least one target site in the 3’-UTR of the examined
mRNAs. Notably four of these miRNAs reside within a
6 kb cluster on the mouse X-chromosome. To our
knowledge, this is the first time that this cluster is corre-
lated to neurogenic cholesterol metabolism. A putative
function of the homologous microRNA cluster in
humans has been recently described. The concerted
regulation of cluster-derived miRNAs promoted cell
cycle arrest and differentiation in myocytes [52] and in
monocytes [53]. Co-expression of clustered miRNAs that
results in cooperative function has been discovered in
several biological systems such as development [54],
stem cell differentiation [55], or viral infection [56].Interestingly we also identified two upregulated miRNAs,
mmu-miR-883a-3p and mmu-miR-743b-5p, that were
localized on a second X-chromosomal cluster. Additional
five miRNAs that reside in this cluster did not match
our stringent criteria, but were upregulated more than
1.5 fold. Whether regulation of these clusters is a cause
or a consequence of prion infection remains unknown.
N2a is a polyploid cell line with a mean number of chro-
mosomes around 100 and an unstable chromosomal
content upon passaging and even within the same cul-
ture [57]. Whether or not the expression of the X-
chromosomal miRNA cluster is also influenced by the
used cell culture conditions cannot be estimated.
It should be noted that the expression of miRNAs are
highly cell- and tissue-specific. Thus differences in
miRNA expression between prion-infected and non-
infected N2a cells may not reflect miRNA dysregulation
in brains of prion-diseased mice or humans. Conse-
quently, the question whether our findings may also have
an indication for human prion diseases cannot be
answered by our study. However, since imbalances in
neuronal cholesterol homeostasis plays a pivotal role in
several human neurodegenerative diseases, including
Alzheimer's disease [58], Huntington’s chorea [59,60],
and Niemann Pick disease type C [61] our results may
be useful to elucidate the mechanism that underlies chol-
esterol dysregulation. Future studies that will focus on
the identification of putative targets of miR-351 and
miR-542-5p need to be carried out to reinforce the sig-
nificance of our results.
Conclusion
We have identified a number of regulated miRNAs in a
cell culture model for prion diseases by the use of ultra-
deep sequencing. Using a joint profiling approach we
found that the X-chromosomal clustered mmu-miRs-351
and 542-5p could target genes that are involved in prion-
induced dysregulation of cholesterol homeostasis. Our
results show that semi-quantitative analysis of ultra-deep
sequencing data is capable to identify differentially regu-
lated miRNAs from biological samples.
Additional file
Additional file 1: miRNA expression profiles of ScN2a and
N2a-mock cells.
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